TYK2 and type 1 diabetes mellitus: To investigate the impact of TYK2 inhibition in a spontaneous preclinical model of T1D, female nonobese diabetic (NOD) mice were treated with either vehicle or 30 mg/kg BMS-986202 for 6 weeks beginning at 6 weeks of age.